Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 1 4Phase 3 2Phase 2 1

Status

Recruiting 2Completed 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Thoracic 1

Conditions

Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 1Advanced ER+, HER2-Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × elacestrant × Clear all
NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
399 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06638307 2026-05-12

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Recruiting
240 enrolled
Breast

Advanced Breast Cancer

NCT02338349 2022-08-18

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
57 enrolled
Breast

Advanced ER+, HER2-Negative Breast Cancer

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Completed
16 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡